FENOFIBRATE

USDailyMed:Fenofibrate AU:B3 C10AB05(WHO)C10BA03(WHO)C10BA04(WHO) AU:S4(Prescription only)UK:POM(Prescription only)US:℞-onlyIn general: ℞ (Prescription only) propan-2-yl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate 49562-28-9Y 3339 7186 DB01039Y 3222Y U202363UOS D00565YC07586Y CHEBI:5001Y ChEMBL672Y DTXSID2029874 Interactive image O=C(c1ccc(Cl)cc1)c2ccc(OC(C(=O)OC(C)C)(C)C)cc2 InChI=1S/C20H21ClO4/c1-13(2)24-19(23)20(3,4)25-17-11-7-15(8-12-17)18(22)14-5-9-16(21)10-6-14/h5-13H,1-4H3YKey:YMTINGFKWWXKFG-UHFFFAOYSA-NY Fenofibrate, sold under the brand nameTricoramong others, is an oral medication of thefibrateclass used to treatabnormal blood lipid levels.It is less commonly used compared to statins because it treats a different type of cholesterol abnormality than statins.‍​‍‍‍​‍‍‍‍‍‍‍‍​‍ While statins have strong evidence for reducing heart disease and death, there is evidence to suggest that fenofibrate also reduces the risk of heart disease and death. However, this seems only to apply to specific populations of people with elevated triglyceride levels and reduced high-density lipoprotein (HDL) cholesterol.Its use is recommended together with dietary changes. Common side effects includeliver problems, breathing problems, abdominal pain, muscle problems, and nausea.Serious side effects may includetoxic epidermal necrolysis,rhabdomyolysis,gallstones, andpancreatitis.Use duringpregnancyandbreastfeedingis not recommended.It works by multiple mechanisms. It was patented in 1969, and came into medical use in 1975.It is available as ageneric medication.In 2023, it was the 83rd most commonly prescribed medication in the United States, with more than 8million prescriptions.